CAMP4 Reports Third Quarter 2026 Financial Results and Corporate Highlights
Globe Newswire•05/11/2026•16:05 ET
0
Key Highlights
- ➤$124.5 million cash supports planned activities through end-2028
- ➤$50.1 million raised in second closing of private placement
- ➤CMP-002 ASCEND Phase 1/2 trial authorized across UK and EU
- ➤CAMP4 remains on track to dose first CMP-002 patient by year-end 2026
- ➤Third-quarter net loss widened to $29.0 million from $15.1 million
Expert Statements
Josh Mandel-Brehm, President and Chief Executive Officer of CAMP4
“The third quarter was one of continued execution for CAMP4. With regulatory clearances now in place in Australia, Argentina, the United Kingdom, and the European Union, we have launched our first-in-human ASCEND Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP1-related disorder.”
Josh Mandel-Brehm, President and Chief Executive Officer of CAMP4
“There are no approved disease-modifying treatments for SYNGAP1, and we are committed to rapidly advancing the development of CMP-002 globally in the hopes of offering SYNGAP1 patients and families a potentially transformative solution that could one day dramatically improve their lives.”
Received authorization in the United Kingdom and European Union to expand global first-in-human ASCEND Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP1-related disorder, adding to clearances in Australia and Argentina
Company remains on track to dose first patient by year-end 2026
Get started
Create a free account to read the full story.